Immunotherapy

Immunotherapy

Summary

immunotherapy is a therapeutic approach that harnesses or modulates the immune system to produce anti-tumor effects, and in this entry it is used as a treatment context for outcome prediction and intervention. In NSCLC, a clinician-deployable deep hypergraph model, deep hypergraph for nsclc, integrated clinical data and CT radiomics to predict immunotherapy outcomes, highlighting a data-driven mechanism for patient stratification (PMID:42008547). In oral precancer, direct immunotherapy injection into lesions was tested in a phase I clinical trial and was associated with tumor shrinkage with no dose-limiting toxicities, suggesting local delivery can be feasible and tolerable (PMID:42012894). In prostate cancer, immunotherapy combined with targeted therapy was evaluated for efficacy and safety, indicating interest in combination regimens rather than monotherapy alone (PMID:42017392). Overall, the provided studies span prediction, local administration, and combination treatment strategies across cancer indications.

Key Findings

NSCLC

  • A clinician-deployable deep hypergraph model, deep hypergraph for nsclc, integrated clinical and CT radiomics to predict immunotherapy outcomes in NSCLC, supporting treatment-response stratification. (PMID:42008547)
  • The study frames immunotherapy as a treatment context for outcome modeling rather than a direct mechanistic target. (PMID:42008547)

Oral precancer

  • Direct immunotherapy injection into oral precancer lesions was associated with tumor shrinkage in a phase I clinical trial. (PMID:42012894)
  • No dose-limiting toxicities were reported, supporting early safety feasibility for local administration. (PMID:42012894)
  • The intervention was delivered directly into lesions, emphasizing a localized treatment strategy. (PMID:42012894)

Prostate cancer

  • Immunotherapy combined with targeted therapy was assessed for efficacy and safety in prostate cancer. (PMID:42017392)
  • The 2026 International Journal of Cancer study focused on clinical benefit, indicating combination therapy as a relevant strategy. (PMID:42017392)
  • This evidence supports evaluation of immunotherapy in multimodal regimens rather than as a standalone approach. (PMID:42017392)